Drugs / Allogeneic BK-specific Cytotoxic T-lymphocytes
Allogeneic BK-specific Cytotoxic T-lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02479698 | Jul 2015 → Jul 2027 expected | AIDS, cutaneous neuroendocrine carcinoma, polyomavirus infectious disease, viral encephalitis | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic BK-specific Cytotoxic T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02479698 ↗ |
| Modality | Cell therapy | “Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory” NCT02479698 ↗ |
| Route | Intravenous | “intravenously (IV)” NCT02479698 ↗ |